Serum Institute of India (SII) to launch the second vaccine by September
SII is developing ‘Covavax’ in collaboration with the US vaccine maker Novavax
The vaccine, reportedly, is 89% efficient against the new COVID-19 variants
Trials for Covavax had begun shortly after DCGI approved SII’s Covishield Vaccine
India began the world’s largest vaccine drive on January 16
Apart from India, SII hopes to roll out Novavax to low and middle-income countries
